On June 1, 2021, DMG Deutsche Malaria GmbH concluded a contract with the EU Malaria Fund (EUMF) to receive €2.7 million for the development of DMG’s antimalarial triple combination therapy. The therapy consists of three known drugs: fosmidomycin, clindamycin, and artesunate (Fos-Clin-Art).
DMG is a Hamburg-based company, founded in 2003 to fight malaria. DMG together with Prof. Kremsner’s group at the University of Tübingen is developing this new combination therapy for Plasmodium falciparum malaria. The triple combination Fos-Clin-Art aims at improving the outcome of both the severe and life-threatening Plasmodium falciparum malaria and of concomitant bacteriaemia. Together, fosmidomycin and clindamycin cover the full spectrum of gram-negative and gram-positive bacteria, and also possess excellent intrinsic antimalarial activity additive to artesunate. Since all three substances have a short half-life, the triple combination is expected to ameliorate and shorten the duration of the needed treatment. The EUMF funding supports DMG’s efforts to conduct the clinical development of Fos-Clin-Art with an overall participant number of more than 5.000 patients in Africa, especially children with severe malaria.
Watch the video on Vimeo here: https://vimeo.com/557723831